# A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State

> **NCT07030439** · PHASE1 · COMPLETED · sponsor: **Impact Therapeutics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd.
- **DRUG:** Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd.

## Key facts

- **NCT ID:** NCT07030439
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-18
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030439, "A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT07030439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*